Thalidomide: rationale for renewed use in immunological disorders.

@article{Schuler1995ThalidomideRF,
  title={Thalidomide: rationale for renewed use in immunological disorders.},
  author={Ulrich S. Schuler and Gerhard Ehninger},
  journal={Drug safety},
  year={1995},
  volume={12 6},
  pages={364-9}
}
Despite its inherent teratogenic risk, thalidomide has over the years proven to be of clinical use in a small number of mainly immunological diseases (e.g. erythema nodosum leprosum, Behçet's syndrome and rheumatoid arthritis). The mode of action of thalidomide is still poorly understood. Recent research has shown a decrease in tumour necrosis factor-alpha (TNF alpha) during thalidomide treatment in several settings. Others have found altered expression of adhesion molecules. Currently, the… CONTINUE READING
15 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…